Author

Colleen W. Marano

FECAL CALPROTECTIN AS A SURROGATE MARKER OF CLINICAL REMISSION, CLINICAL RESPONSE, ENDOSCOPIC IMPROVEMENT, AND HISTO-ENDOSCOPIC MUCOSAL HEALING: UNIFI INDUCTION STUDY
FECAL CALPROTECTIN AS A SURROGATE MARKER OF CLINICAL REMISSION, CLINICAL RESPONSE, ENDOSCOPIC IMPROVEMENT, AND HISTO-ENDOSCOPIC MUCOSAL HEALING: UNIFI INDUCTION STUDY

Colleen W. Marano  et al.

EFFECT OF USTEKINUMAB MAINTENANCE THERAPY ON STOOL FREQUENCY AND RECTAL BLEEDING THROUGH 2 YEARS IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
EFFECT OF USTEKINUMAB MAINTENANCE THERAPY ON STOOL FREQUENCY AND RECTAL BLEEDING THROUGH 2 YEARS IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Colleen W. Marano  et al.

ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS
ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS

Colleen W. Marano  et al.

EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SUBPOPULATION ANALYSIS OF UNIFI LONG-TERM EXTENSION THROUGH 3 YEARS
EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SUBPOPULATION ANALYSIS OF UNIFI LONG-TERM EXTENSION THROUGH 3 YEARS

Colleen W. Marano  et al.

LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS
LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS

Colleen W. Marano  et al.

PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY
PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

Colleen W. Marano  et al.

CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION
CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION

Colleen W. Marano  et al.

EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION
EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION

Colleen W. Marano  et al.

AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY
AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY

Colleen W. Marano  et al.

EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Colleen W. Marano  et al.

SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS
SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS

Colleen W. Marano  et al.

EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION
EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION

Colleen W. Marano  et al.

Item 1 - 12 / 12
1